Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)

Bart J. Biemond, MD PhD, Anil Tombak, MD, Yurdanur Kilinc, MD, Murtadha Al-Khabori, MD, Miguel R. Abboud, MD, Mohammed Nafea, MD, Adlette Inati, MD, Yasser Ahmed Mohamed Soliman Wali, MD, Jens Kristensen, MD PhD, Ellen Donnelly, PhD, John Ohd, MD PhD

Blood (2019) 134 (Supplement_1): 614.

https://doi.org/10.1182/blood-2019-124653

Published: 2019

Journal Articles

Role for PARS and Thrombin-Gpibα Interaction for Thrombin Induced Procoagulant Platelet Formation

Morgane Bourcy, PhD, Leonardo Pasalic, MBBS, BSc, Samuel Wang, Heather Campbell, BSc, Hai Po Helena Liang, PhD, Vivien Chen, PhD FRACP, FRCPA, MBBS

Blood (2017) 130 (Supplement 1): 3607.

https://doi.org/10.1182/blood.V130.Suppl_1.3607.3607

Published: 2017

Journal Articles

Sevuparin Blocks Sickle Blood Cell Adhesion and Sickle-Leukocyte Rolling on Immobilized L-Selectin in a Dose Dependent Manner

Maria Lindgren, PhD, Jennell White, PhD, Ke Liu, PhD, Lena Jendeberg, PhD, Patrick C. Hines, MD PhD

Blood (2016) 128 (22): 2482.

https://doi.org/10.1182/blood.V128.22.2482.2482

Published: 2016

Journal Articles

Assessment of Risk of Thromboprophylaxis Failure in Hospitalized Patients with Cancer (Artic Study)

Martha L Louzada, BSc, MD MSc, Michael J. Kovacs, MD, FAtimah Al-Ani, MD, Alejandro Lazo-Langner, MD MSc, Lenicio Siqueira

Blood (2014) 124 (21): 588.

https://doi.org/10.1182/blood.V124.21.588.588

Published: 2014

Journal Articles

The Architecture Of Fibrin Clots Formed From Plasma With Low Platelet Levels Are Less Altered In The Presence Of Factor-Specific Anticoagulants Compared With Unfractionated Heparin

Jorell Gantioqui, MSc candidate, Ivan Stevic, PhD, Paul Y. Kim, PhD, Keith K. Lau, MBBS, FRCP(C), FRCP(Lond), Anthony K.C. Chan, MBBS, FRCPC, FRCPath, Howard H.W. Chan, MBChB, FRCPC, MSc, FRCP(Glasg), FRCP(Ireland)

Blood (2013) 122 (21): 578.

https://doi.org/10.1182/blood.V122.21.578.578

Published: 2013

Journal Articles

An in-Vitro Model Using Thromboelastography to Evaluate the Effects of Anticoagulants On Clot Formation in Plasma Enriched with Autologous Platelets

Jorell Gantioqui, MSc candidate, Ivan Stevic, MSc, PhD candidate, Paul Y. Kim, PhD, Keith K. Lau, MD, Anthony K.C. Chan, MBBS, FRCPC, FRCPath, Howard H.W. Chan, MBChB, FRCPC, MSc

Blood (2012) 120 (21): 1091.

https://doi.org/10.1182/blood.V120.21.1091.1091

Published: 2012

Journal Articles

Size matters

Andras Gruber, Erik I. Tucker

Blood (2011) 118 (25): 6481–6482.

https://doi.org/10.1182/blood-2011-10-382622

Published: 2011

Journal Articles

Molecular Mimicry in the Adulteration of Heparins. Chemical Basis for the Development of Oversulfated Chondroitin Sulfate and Related Contaminants

Jawed Fareed, PhD, Rakesh Wahi, MD, Indermohan Thethi, MD, Debra Hoppensteadt, Ph.D., Vinod Bansal, MD, Jeanine M. Walenga, PhD, Harry L. Messmore, MD

Blood (2011) 118 (21): 4322.

https://doi.org/10.1182/blood.V118.21.4322.4322

Published: 2011

Journal Articles

The Efficacy of Prophylactic Use of Antithrombin with Unfractionated Heparin or Danaparoid Sodium to Prevent Venous Thromboembolism In Children with Acute Lymphoblastic Leukemia

Hirotoshi Sakaguchi, MD, Nao Yoshida, MD, PhD, Kimikazu Matsumoto, MD, PhD, Koji Kato, MD, PhD

Blood (2010) 116 (21): 2123.

https://doi.org/10.1182/blood.V116.21.2123.2123

Published: 2010

Journal Articles

Seroprevalence of PF4/Heparin Antibodies among Blood Bank Donors

Poulomi J. Pai, MD, Julianna E McCracken, Gowthami M Arepally, MD

Blood (2008) 112 (11): 4536.

https://doi.org/10.1182/blood.V112.11.4536.4536

Published: 2008

Journal Articles

Selectins, Heparins, and Cancer: Rationale for Clinical Trials.

Ajit P. Varki, MD, Nissi M. Varki, MD, Lubor Borsig

Blood (2008) 112 (11): sci-20.

https://doi.org/10.1182/blood.V112.11.sci-20.sci-20

Published: 2008

Journal Articles

Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).

Jakub Tolar, MD, PhD, Paul J. Orchard, M.D., Nigel Key, M.D., Bruce R. Blazar, M.D.

Blood (2007) 110 (11): 2160.5.

https://doi.org/10.1182/blood.V110.11.2160.5.2160.5

Published: 2007

Journal Articles

AVE5026: A Novel, Extractive Heparinoid with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity.

Debra Hoppensteadt, PhD, Josephine Cunanan, M.D., Eric Geniaux, Ph.D., Martin Lorenz, Ph.D., Christian Viskov, Ph.D., Pascal Ythier-Moury, Ph.D., Jean-Francois Brin, M.D., Walter Jeske, Ph.D.

Blood (2007) 110 (11): 1881.

https://doi.org/10.1182/blood.V110.11.1881.1881

Published: 2007

Journal Articles

Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).

Jakub Tolar, MD, PhD, Paul J. Orchard, M.D., Nigel Key, M.D., Bruce R. Blazar, M.D.

Blood (2007) 110 (11): 3951.

https://doi.org/10.1182/blood.V110.11.3951.3951

Published: 2007

Journal Articles

AVE5026, a New Anticoagulant for the Prevention of Venous Thromboembolism in Total Knee Replacement Surgery - TREK: A Dose Ranging Study.

Michael R. Lassen, MD, Ola E. Dahl, MD, Patrick Mismetti, MD, Dominique Destrée, MD

Blood (2007) 110 (11): 311.

https://doi.org/10.1182/blood.V110.11.311.311

Published: 2007

Journal Articles

Antidotal Effects of rFVIIa and FEIBA on Anticoagulant-Induced Inhibition of Thrombin Generation.

Daniele Pillitteri, MSc, Wolfgang Wegert, MSc, Thomas Scholz, Carl M. Kirchmaier, MD

Blood (2006) 108 (11): 4124.

https://doi.org/10.1182/blood.V108.11.4124.4124

Published: 2006

Journal Articles

Reversal of Anticoagulation as Assessed by Thrombin Generation Measurement.

Alex Gatt, MD, Joost van Veen, MD, Peter Cooper, Steve Kitchen, PhD, Michael Makris, MD

Blood (2006) 108 (11): 876.

https://doi.org/10.1182/blood.V108.11.876.876

Published: 2006

Journal Articles

Implications of Heparinoid-Induced Inactivation of Coagulation Cascade Factors and In Vivo Proenzyme Concentration.

Sanjay Patel, MSc, Leslie R. Berry, BSc, Mark W.C. Hatton, PhD, Anthony Chan, MBBS

Blood (2006) 108 (11): 1621.

https://doi.org/10.1182/blood.V108.11.1621.1621

Published: 2006

Journal Articles

In Vitro Effect of Danaparoid Sodium (Orgaran ® ) on Thrombin Generation after Minimal Tissue Factor Pathway Activation.

Ismail Elalamy, MD, PhD, Anna D. Petropoulou, MD, Mohamed Hatmi, PhD, Meyer M. Samama, Grigoris T. Gerotziafas, MD, PhD

Blood (2005) 106 (11): 4151.

https://doi.org/10.1182/blood.V106.11.4151.4151

Published: 2005

Journal Articles

Evaluating the Outcomes of Quality Improvement Initiatives of a Multi-Disciplinary Heparin-Induced Thrombocytopenia (HIT) Task Force.

Elaine A. Davis, EdD, James Norman Frame, MD, Ying Wang, PhD, Joan Reed, MS

Blood (2005) 106 (11): 2252.

https://doi.org/10.1182/blood.V106.11.2252.2252

Published: 2005

NARROW

Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)

Role for PARS and Thrombin-Gpibα Interaction for Thrombin Induced Procoagulant Platelet Formation

Sevuparin Blocks Sickle Blood Cell Adhesion and Sickle-Leukocyte Rolling on Immobilized L-Selectin in a Dose Dependent Manner

Assessment of Risk of Thromboprophylaxis Failure in Hospitalized Patients with Cancer (Artic Study)

The Architecture Of Fibrin Clots Formed From Plasma With Low Platelet Levels Are Less Altered In The Presence Of Factor-Specific Anticoagulants Compared With Unfractionated Heparin

An in-Vitro Model Using Thromboelastography to Evaluate the Effects of Anticoagulants On Clot Formation in Plasma Enriched with Autologous Platelets

Size matters

Molecular Mimicry in the Adulteration of Heparins. Chemical Basis for the Development of Oversulfated Chondroitin Sulfate and Related Contaminants

The Efficacy of Prophylactic Use of Antithrombin with Unfractionated Heparin or Danaparoid Sodium to Prevent Venous Thromboembolism In Children with Acute Lymphoblastic Leukemia

Seroprevalence of PF4/Heparin Antibodies among Blood Bank Donors

Selectins, Heparins, and Cancer: Rationale for Clinical Trials.

Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).

AVE5026: A Novel, Extractive Heparinoid with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity.

Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).

AVE5026, a New Anticoagulant for the Prevention of Venous Thromboembolism in Total Knee Replacement Surgery - TREK: A Dose Ranging Study.

Antidotal Effects of rFVIIa and FEIBA on Anticoagulant-Induced Inhibition of Thrombin Generation.

Reversal of Anticoagulation as Assessed by Thrombin Generation Measurement.

Implications of Heparinoid-Induced Inactivation of Coagulation Cascade Factors and In Vivo Proenzyme Concentration.

In Vitro Effect of Danaparoid Sodium (Orgaran ® ) on Thrombin Generation after Minimal Tissue Factor Pathway Activation.

Evaluating the Outcomes of Quality Improvement Initiatives of a Multi-Disciplinary Heparin-Induced Thrombocytopenia (HIT) Task Force.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only